Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation

By: EFPIA MID3 WorkgroupSF MarshallR BurghausV CossonSYA CheungM ChenelO DellaPasquaN FreyB HamrénL HarnischF IvanowT KerbuschJ LippertPA MilliganS RohouA StaabJL SteimerC TornøeSAG Visser

Abstract

This document was developed to enable greater consistency in the practice, application, and documentation of Model‐Informed Drug Discovery and Development (MID3) across the pharmaceutical industry. A collection of “good practice” recommendations are assembled here in order to minimize the heterogeneity in both the quality and content of MID3 implementation and documentation. The three major objectives of this white paper are to: i) inform company decision makers how the strategic integration of MID3 can benefit R&D efficiency; ii) provide MID3 analysts with sufficient material to enhance the planning, rigor, and consistency of the application of MID3; and iii) provide regulatory authorities with substrate to develop MID3 related and/or MID3 enabled guidelines.

返回顶部
Powered by Translations.com GlobalLink OneLink Software